News | 30 January 2013
The overall ratings of six Biotechnology stocks are down on Portfolio Grader this week. Each of these rates a ?D? (?sell?) or ?F? overall (?strong sell?). This week, Achillion (NASDAQ:ACHN) falls to a D (?sell?), worse than last week's grade of C ...
Click on the link to read the full article at Investorplace.com
(This link will open in a new window)